Novo Nordisk's CagriSema Misses Primary Endpoint, Shares Decline

Novo Nordisk's experimental weight-loss drug, CagriSema, did not meet its primary endpoint in a late-stage clinical trial, failing to demonstrate non-inferiority compared to Eli Lilly's tirzepatide on weight loss after 84 weeks. Following this announcement, the company's Copenhagen-listed shares experienced a significant decline.

Novo Nordisk's experimental weight-loss drug, CagriSema, did not meet its primary endpoint in a late-stage clinical trial, failing to demonstrate non-inferiority compared to Eli Lilly's tirzepatide on weight loss after 84 weeks.

Despite the setback, Novo Nordisk has indicated plans for further trials, including higher-dose combinations. The company also anticipates a decision from the US drug regulator on the medication later this year, based on earlier trial data.

Trial Results Detailed

CagriSema, a weekly injection, combines cagrilintide (which mimics the pancreatic hormone amylin) and semaglutide (an active ingredient in Wegovy and Ozempic that mimics the gut hormone GLP-1). The clinical trial was conducted to assess its efficacy, specifically aiming to demonstrate that CagriSema was at least as effective as Eli Lilly's anti-obesity drug Zepbound, which contains tirzepatide.

Key findings from the trial include:

• CagriSema did not achieve its primary endpoint of demonstrating non-inferiority on weight loss when compared to tirzepatide after 84 weeks.
• Patients receiving a 2.4 mg dose of CagriSema achieved an average weight loss of 23% over 84 weeks.
• In comparison, patients receiving a 15 mg dose of tirzepatide achieved an average weight loss of 25.5% over the same period.

Company Response and Future Plans

Novo Nordisk has stated its intention to explore additional trials for CagriSema, which may include higher-dose combinations. The company remains optimistic, anticipating that a separate study involving a higher CagriSema dose could potentially yield improved results.

Martin Holst Lange, Novo Nordisk's Chief Scientific Officer, commented on the drug's potential.

"CagriSema's potential to be the first GLP-1/amylin-combination product for obesity... offers clinically meaningful additive weight loss effects superior to GLP-1 biology alone."

Novo Nordisk CEO Mike Doustdar characterized CagriSema as "a fantastic drug." He asserted that upon its market entry, it will offer the "best weight-loss label" among amylin-based products. The medication has already been submitted to the US drug regulator for approval based on earlier trial evidence, with a decision expected later this year.

Market Impact and Context

Following the trial results announcement, Novo Nordisk's Copenhagen-listed shares decreased by 15% to 16.5%, reaching their lowest level since June 2021. This contributed to reported losses of nearly 60% in the company's shares over the past year. In stark contrast, Eli Lilly's stock rose by 4.3% on Wall Street.

In the broader market context, Eli Lilly's tirzepatide products, Mounjaro and Zepbound, have reportedly surpassed Novo Nordisk's semaglutide products, Ozempic and Wegovy, in U.S. prescriptions.

Analysts at Deutsche Bank suggested that CagriSema appeared less competitive.

"CagriSema appeared less competitive as an upgrade to semaglutide or an alternative to tirzepatide."

Earlier in the month, Novo Nordisk had projected a decline in its sales and profit growth by 5% to 13% in 2026. This projection was attributed to market competition, lower prices in the U.S., and the loss of exclusivity for Wegovy and Ozempic in certain markets. CEO Mike Doustdar had previously stated that a decline should be expected before a recovery.